A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)-Reference-Cited by-同舟云学术

A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Published:2016-02 Issue: Volume:54 Page:11-17
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Flinn Ian W.,Bartlett Nancy L.,Blum Kristie A.,Ardeshna Kirit M.,LaCasce Ann S.,Flowers Christopher R.,Shustov Andrei R.,Thress Kenneth S.,Mitchell Patrick,Zheng Fred,Skolnik Jeffrey M.,Friedberg Jonathan W.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference32 articles.

1. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002

2. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling;Alizadeh;Nature,2000

3. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma;Chen;Blood,2008

4. The SYK tyrosine kinase: a crucial player in diverse biological functions;Mócsai;Nat Rev Immunol,2010

5. Mechanisms of B-cell lymphoma pathogenesis;Kuppers;Nature Reviews Cancer,2005

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current status and future perspectives of platelet-derived extracellular vesicles in cancer diagnosis and treatment;Biomarker Research;2024-08-26

2. Spleen tyrosine kinase (SYK): an emerging target for the assemblage of small molecule antitumor agents;Expert Opinion on Investigational Drugs;2024-08-11

3. Post-marketing safety surveillance of fostamatinib: an observational, pharmacovigilance study leveraging FAERS database;Expert Opinion on Drug Safety;2024-08

4. Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors;Haematologica;2024-01-18

5. Review and prospects of targeted therapies for Spleen tyrosine kinase (SYK);Bioorganic & Medicinal Chemistry;2023-12